

Rec'd PCT/PTO 07 DEC 2004
#2

PC AU03/00717



REC'D 24 JUN 2003

WIPO PCT

Patent Office
Canberra

I, JONNE YABSLEY, TEAM LEADER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. PS 2832 for a patent by MONASH UNIVERSITY as filed on 07 June 2002.



WITNESS my hand this
Seventeenth day of June 2003

JONNE YABSLEY
TEAM LEADER EXAMINATION
SUPPORT AND SALES

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

A U S T R A L I A

Patents Act 1990

PROVISIONAL SPECIFICATION

for the invention entitled:

"Therapeutic molecules and methods – 1"

The invention is described in the following statement:

THERAPEUTIC MOLECULES AND METHODS – 1

FIELD OF THE INVENTION

5 The present invention relates generally to the treatment of diseases or conditions resulting from cellular activation, such as inflammatory or cancerous diseases or conditions. In particular, the invention relates to the use of heterocyclic derivatives to inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biological activity is implicated.

10

BACKGROUND OF THE INVENTION

MIF is the first identified T-cell-derived soluble lymphokine. MIF was first described as a soluble factor with the ability to modify the migration of macrophages (1). The molecule
15 responsible for the biological actions ascribed to MIF was identified and cloned in 1989 (2). Initially found to activate macrophages at inflammatory sites, it has been shown to possess pluripotential actions in the immune system. MIF has been shown to be expressed in human diseases which include inflammation, injury, ischaemia or malignancy. MIF also has a unique relationship with glucocorticoids by overriding their anti-inflammatory
20 effects.

Recent studies have indicated that monoclonal antibody antagonism of MIF may be useful in the treatment of sepsis, certain types of cancers and delayed type hypersensitivity. Antibody antagonism of MIF has also been shown to have activity in adjuvant- or
25 collagen-induced arthritis animal models and other models of inflammatory and immune diseases.

Although antibody antagonism of MIF is one potential way to provide therapeutic treatments, such biological molecules can be expensive to prepare on a commercial basis
30 and further, can be limited in the way they are administered (generally by injection) and do not readily lend themselves to formulations for administration by other means eg oral

- 2 -


administration.

Small molecule inhibitors may overcome one or more such difficulties connected with the use of biological therapeutic treatments. There exists a need, therefore, for small molecule inhibitors of the cytokine or biological activity of MIF.

SUMMARY OF THE INVENTION

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

In a first aspect, the present invention provides a method of inhibiting cytokine or biological activity of MIF comprising contacting MIF with a cytokine or biological activity inhibiting effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof



20

wherein

X comprises a hydrogen bond donor or acceptor and is preferably selected from -O-, -S-, -C(R₅)(R_{5'})- or -N(R₆)-;

25 Y is selected from -N(R₇)- or -C(R₇)₂-;

Z is selected from $-C(O)-$, $-C(S)-$, $-C(=NR_6)-$, $-S(O)-$ or $-S(O)_2-$;

R_1 is selected from hydrogen, C_{1-3} alkyl, $(CR_5R_{5'})_nOR_7$, $(CR_5R_{5'})_nSR_7$, $(CR_5R_{5'})_nN(R_6)_2$ and $(CR_5R_{5'})_n$ halo;

5

R_2 is selected from C_1-C_{20} alkyl, C_2-C_{20} alkenyl, C_2-C_{20} alkynyl, $(CR_{12}R_{12'})_mC(O)R_8$, $(CR_{12}R_{12'})_mC(S)R_8$, $(CR_{12}R_{12'})_mS(O)R_8$, $(CR_{12}R_{12'})_mS(O)_2R_8$, $(CR_{12}R_{12'})_mOR_9$, $(CR_{12}R_{12'})_mSR_9$, $(CR_{12}R_{12'})_mNR_{10}R_{11}$, $(CR_{12}R_{12'})_mC(=NR_{24})R_{22}$ and $(CR_{12}R_{12'})_mR_{13}$;

10 R_3 is selected from hydrogen, C_1-C_6 alkyl, $(CR_{16}R_{16'})_pNR_{14}R_{15}$, $(CR_{16}R_{16'})_pOR_{17}$, $(CR_{16}R_{16'})_pSR_{17}$, $(CR_{16}R_{16'})_p$ halo, $(CR_{16}R_{16'})_nC(O)R_{28}$, $(CR_{16}R_{16'})_nC(=NR_{24})R_{22}$, $(CR_{16}R_{16'})_nS(O)R_{17}$, $(CR_{16}R_{16'})_nS(O)_2R_{17}$, $(CR_{16}R_{16'})_nS(O)_3R_{17}$ and $(CR_{16}R_{16'})_pC(R_{18})_3$;

R_4 is selected from hydrogen, C_1-C_3 alkyl, C_2-3 alkenyl, C_2-3 alkynyl and $(CR_{12}R_{12'})_nC(R_{18})_3$;

15

Each R_5 and $R_{5'}$ is independently selected from hydrogen, C_1-C_3 alkyl, halo, OR_7 , SR_7 and $N(R_6)_2$;

Each R_6 is independently selected from hydrogen, C_1-C_3 alkyl and OR_7 ;

20

Each R_7 is independently selected from hydrogen and C_1-C_3 alkyl;

R_8 is selected from hydrogen, C_1-C_{20} alkyl, C_2-C_{20} alkenyl, C_2-C_{20} alkynyl, OR_{19} , SR_{19} , $N(R_{20})_2$, $[NH-CH(R_{21})-C(O)]_q-OR_{29}$, [sugar]_q and $(CR_{12}R_{12'})_tR_{13}$;

25

R_9 is selected from hydrogen, C_1-C_{20} alkyl, C_2-C_{20} alkenyl, C_2-C_{20} alkynyl, $(CR_{12}R_{12'})_tR_{13}$, $C(O)R_{23}$, CO_2R_{23} , $C(S)R_{23}$, $C(S)OR_{23}$, $S(O)R_{23}$, $S(O)_2R_{23}$, $[C(O)CH(R_{21})NH]_q-R_{23}$ and [sugar]_q;

30 R_{10} and R_{11} are independently selected from hydrogen, C_1-C_{20} alkyl, C_2-C_{20} alkenyl, C_2-C_{20} alkynyl, $(CR_{12}R_{12'})_mR_{13}$, $C(O)R_{23}$, $C(S)R_{23}$, $S(O)R_{23}$, $S(O)_2R_{23}$,

$[C(O)CH(R_{21})NH]_q-R_{23}$, $-[sugar]_q$ and $NHC(=NR_{25})-NH_2$;

Each R_{12} and $R_{12'}$ is independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, OR_{24} , SR_{24} , halo, $N(R_{24})_2$, CO_2R_{24} , CN, NO_2 , aryl or heterocyclyl;

5

R_{13} is selected from OR_{25} , SR_{25} , halo, $N(R_{25})_2$, $C(O)R_{31}$, CN, $C(R_{18})_3$, aryl or heterocyclyl;

R_{14} and R_{15} are independently selected from hydrogen, C_1 - C_3 alkyl, OR_{17} , $(CR_{16}R_{16'})_pC(R_{18})_3$;

10

Each R_{16} and $R_{16'}$ is independently selected from hydrogen, C_1 - C_3 alkyl, halo, OR_{17} , SR_{17} and $N(R_{17})_2$;

Each R_{17} is independently selected from hydrogen and C_1 - C_3 alkyl;

15

Each R_{18} is independently selected from hydrogen and halo;

R_{19} and each R_{20} are independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $(CR_{26}R_{26'})_tR_{27}$;

20

R_{21} is the characterising group of an amino acid;

R_{22} is selected from C_1 - C_6 alkyl, NH_2 , $NH(C_{1-3}alkyl)$, $N(C_{1-3}alkyl)_2$, OR_{29} or SR_{29} ;

25 R_{23} is selected from hydrogen, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, aryl $(CR_{26}R_{26'})_tR_{27}$;

Each R_{24} is independently selected from hydrogen and C_1 - C_6 alkyl;

30 Each R_{25} is independently selected from hydrogen, C_1 - C_6 alkyl, $C_{1-3}alkoxyC_{1-3}alkyl$, aryl and heterocyclyl;

Each R_{26} and $R_{26'}$ is independently selected from hydrogen, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, OR_{29} , SR_{29} , halo, $N(R_{29})_2$, CO_2R_{29} , CN, NO_2 , aryl and heterocyclyl;

5 R_{27} is selected from hydrogen, OR_{30} , SR_{30} , halo, $N(R_{30})_2$, CO_2R_{30} , aryl and heterocyclyl;

R_{28} is selected from hydrogen, C_1 - C_6 alkyl, OR_{29} , SR_{29} or $N(R_{29})_2$;

Each R_{29} is independently selected from hydrogen and C_1 - C_3 alkyl;

10

Each R_{30} is independently selected from hydrogen, C_1 - C_3 alkyl, aryl and heterocyclyl;

R_{31} is selected from C_1 - C_3 alkyl, OH, C_1 - C_3 alkoxy, aryl, aryloxy, heterocyclyl and heterocyclloxy;

15

n is 0 or an integer from 1 to 3;

m is 0 or an integer from 1 to 20;

p is 0 or an integer from 1 to 6;

q is an integer from 1 to 5;

20 t is an integer from 1 to 6;

wherein alkyl, alkenyl, alkynyl, aryl and heterocyclyl may be optionally substituted with one or more halogen, hydroxy, alkoxy, C_1 - C_6 alkyl, carboxylic acid, carboxylic ester, amino, alkyl substituted amino, -CN, or - NO_2 .

25

In another aspect, the invention provides a method of treating, preventing or diagnosing a disease or condition wherein MIF cytokine or biological activity is implicated comprising the administration of a treatment, prevention or diagnostic effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof to a subject in need

30 thereof.

BEST AVAILABLE COPY

In a further aspect, there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment, prevention or diagnosis of a disease or condition wherein MIF cytokine or biological activity is implicated.

5

In particular, the invention provides a method of treating, diagnosing or preventing autoimmune diseases, solid or haemopoietic tumours, or chronic or acute inflammatory diseases, including a disease or condition selected from the group comprising:

10

Rheumatic diseases (including but not limited to rheumatoid arthritis, osteoarthritis, psoriatic arthritis) spondyloarthropathies (including but not limited to ankylosing spondylitis, reactive arthritis, Reiter's syndrome), crystal arthropathies (including but not limited to gout, pseudogout, calcium pyrophosphate deposition disease), Lyme disease, connective tissue diseases (including but not limited to systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, Sjögren's syndrome), vasculitides (including but not limited to polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome), glomerulonephritis, inflammatory bowel disease (including ulcerative colitis, Crohn's disease), peptic ulceration, gastritis, oesophagitis, liver disease (including but not limited to cirrhosis, hepatitis), autoimmune diseases (including but not limited to diabetes mellitus, thyroiditis, myasthenia gravis, sclerosing cholangitis, primary biliary cirrhosis), pulmonary diseases (including but not limited to diffuse interstitial lung diseases, pneumoconioses, fibrosing alveolitis, asthma, bronchitis, bronchiostasis, chronic obstructive pulmonary disease, adult respiratory distress syndrome), cancers whether primary or metastatic (including but not limited to colon cancer, lymphoma, lung cancer, melanoma, prostate cancer, breast cancer, stomach cancer, leukemia, cervical cancer and metastatic cancer), atherosclerosis (eg ischaemic heart disease, myocardial infarction, stroke, peripheral vascular disease), disorders of the hypothalamic-pituitary-adrenal axis, brain disorders (eg Alzheimers, multiple sclerosis), corneal disease, iritis, iridocyclitis, cataracts, uveitis, sarcoidosis, diseases characterised by modified angiogenesis (eg diabetic retinopathy,

20

25

30

- 7 -

5 rheumatoid arthritis, cancer), endometrial function (menstruation, implantation, endometriosis), psoriasis, endotoxic (septic) shock, exotoxic (septic) shock, infective (true septic) shock, other complications of infection, pelvic inflammatory disease, transplant rejection, allergies, allergic rhinitis, bone diseases (eg osteoporosis, Paget's disease), atopic dermatitis, UV(B)-induced dermal cell activation (eg sunburn, skin cancer), malarial complications, diabetes mellitus, pain, inflammatory consequences of trauma or ischaemia, testicular dysfunctions and wound healing,

10 comprising the administration of a treatment, diagnosis or prevention effective amount of a compound of Formula (I) to a subject in need thereof.

A further aspect of the invention provides for the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a disease or condition as above.

15 The compounds of formula (I) may also have an inhibitory effect on the tautomerase activity also associated with MIF. This may form a further aspect of the invention.

In preferred embodiments, the compounds of Formula (I) are used to treat or prevent a disease or condition, particularly in a human subject.

20 Certain compounds of Formula (I) are novel, and these form a further aspect of the present invention.

BRIEF DESCRIPTION OF THE FIGURES

25 Figure 1 graphically depicts dose response effect of 1 μ m, 10 μ m, 50 μ m and 100 μ m of benzimidazol-2-one-5-pentanoate (compound 5) on Interleukin-1 (IL-1)-induced cyclooxygenase II (COX-2) expression.

30 ~~Figure 2 graphically depicts the effect of a combination of dexamethasone and benzimidazol-2-one-5-pentanoate (compound 5) on IL-1 induced COX-2~~

BEST AVAILABLE COPY

expression.

Figure 3 graphically depicts the effect of benzimidazol-2-one-5-pentanoate (compound 5) on *in vivo* serum IL-6 production in a murine endotoxic shock model.

Figure 4 graphically depicts the effect of benzimidazol-2-one-5-pentanoate (compound 5) on *in vivo* serum IL-1 production in a murine endotoxic shock model.

Figure 5 graphically depicts the toxicity effect of benzimidazol-2-one-5-pentanoate (compound 5) on *in vitro* S112 cells.

Figure 6 graphically depicts the toxicity effect of a number of compounds of formula (I) on *in vitro* S112 cells.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "alkyl" refers to monovalent straight, branched or, where appropriate, cyclic aliphatic radicals, having 1 to 3, 1 to 6, 1 to 10 or 1 to 20 carbon atoms, e.g. methyl, ethyl, *n*-propyl, *iso*-propyl, cyclopropyl, *n*-butyl, *sec*-butyl, *t*-butyl and cyclobutyl, *n*-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, *n*-hexyl, 1- 2- 3- or 4- methylpentyl, 1- 2- or 3-ethylbutyl, 1 or 2- propylpropyl or cyclohexyl.

An alkyl group may be optionally substituted one or more times by halo (eg chloro, fluoro or bromo), CN, NO₂, CO₂H, CO₂C₁₋₆alkyl, OH, alkoxy, carboxy, carboxyalkyl, NH₂, NH(C₁₋₆alkyl) or NH(C₁₋₆alkyl)₂. A preferred optional substituent is a polar substituent. Examples of alkoxy include methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, cyclopropoxy, and butoxy (*n*-, *sec*- *t*- and cyclo) pentoxy and hexyloxy. The "alkyl" portion of an alkoxy group may be substituted as described above.

As used herein, the term "alkenyl" refers to straight, branched, or where appropriate, cyclic carbon containing radicals having one or more double bonds between carbon atoms. Examples of such radicals include vinyl, allyl, butenyl, or longer carbon chains such as those derived from palmitoleic, oleic, linoleic, linolenic or arachidonic acids. An alkenyl group may be optionally substituted one or more times by halo (eg chloro, fluoro or bromo), CN, NO₂, CO₂H, CO₂C₁₋₆alkyl, OH, alkoxy, carboxy, carboxyalkyl, NH₂, NH(C₁₋₆alkyl) or NH(C₁₋₆alkyl)₂. A preferred optional substituent is a polar substituent.

As used herein, the term "alkynyl" refers to straight or branched carbon containing radicals having one or more triple bonds between carbon atoms. Examples of such radicals include propargyl, butynyl and hexynyl. An alkynyl group may be optionally substituted one or more times by halo (eg chloro, fluoro or bromo), CN, NO₂, CO₂H, CO₂C₁₋₆alkyl, OH, alkoxy, carboxy, carboxyalkyl, NH₂, NH(C₁₋₆alkyl) or NH(C₁₋₆alkyl)₂. A preferred optional substituent is a polar substituent.

Examples of suitable NH(alkyl) and N(alkyl)₂ include methylamino, ethylamino, isopropylamino, dimethylamino, n-propylamino, diethylamino and di-isopropylamino.

The term "halogen" (or "halo") refers to fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo).

The term "sugar" refers to a pyranosyl or furanosyl moiety such as those derived from glucose, galactose, mannose, allose, altrose, gluose, idose, talose, ribose, arabinose or xylose.

As used herein, "the characterising group of an amino acid" refers to the substituent at C₂ of an amino acid and which defines the amino acid. For example, methyl is the characterising group of alanine, phenylmethyl is the characterising group of phenylalanine and hydroxymethyl is the characterising group of serine.

30

An aryl group, as used herein, refers to C₆-C₁₀ aryl groups such as phenyl or naphthalene.

BEST AVAILABLE COPY

Aryl groups may be optionally substituted one or more times by halo (eg, chloro, fluoro or bromo), CN, NO₂, CO₂H, CO₂C₁₋₆alkyl, OH, alkyl, alkoxy, carboxy, carboxyalkyl, NH₂, NH(alkyl) or N(alkyl)₂.

- 5 As used herein, the term "heterocyclyl" refers to a cyclic, aliphatic or aromatic radical containing at least one heteroatom independently selected from O, N or S. Examples of suitable heterocyclyl groups include furyl, pyridinyl, pyrimidinyl, pyrazolyl, piperidinyl, pyrrolyl, thiaphenyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, isothiazolyl, quinolyl, isoquinolyl, indolyl, benzofuranyl, benzothiophenyl, triazolyl, terazolyl, oxadiazolyl and
 10 purinyl. Heterocyclyl groups may be optionally substituted one or more times by halo (eg, chloro, fluoro or bromo), CN, NO₂, CO₂H, CO₂C₁₋₆alkyl, OH, alkyl, alkoxy, carboxy, carboxyalkyl, NH₂, NH(alkyl) or N(alkyl)₂.

In a preferred embodiment one or more of the following definitions apply:

15

X is -N(H)-, -N(C₁₋₃alkyl), -N(OH)-, -N(OC₁₋₃alkyl), -O-, -CH₂-, -CH(OH)-, -CH(NH₂)-, -CH(C₁₋₃alkyl)-, -CH(halo)-, -CH(SH)-, -CH(OC₁₋₃alkyl), -CH(SC₁₋₃alkyl)-;

Y is -NH-, -N(C₁₋₃alkyl)-;

20

Z is -C(O)-, -C(S)-, -C(=NH)-, -C(=NC₁₋₃alkyl)-, -C(=NOH)- or -C(=NOC₁₋₃alkyl);

R₁ is hydrogen, OH, SH, NH₂, F or Cl;

- 25 R₂ is selected from C₁₋₂₀alkyl, C₁₋₂₀alkenyl, (CR₁₂R_{12'})_mOH, (CR₁₂R_{12'})_mOC₁₋₂₀alkyl, (CR₁₂R_{12'})_mOC₁₋₂₀alkenyl, (CR₁₂R_{12'})_mOC(O)C₁₋₂₀alkyl, (CR₁₂R_{12'})_mOC(O)C₁₋₂₀alkenyl, (CR₁₂R_{12'})_mOC(O)aryl, (CR₁₂R_{12'})_mO[C(O)CH(R₂₁)NH]_r-H, (CR₁₂R_{12'})_mO[sugar]_r, (CR₁₂R_{12'})_mNHC₁₋₂₀alkyl, (CR₁₂R_{12'})_mN(C₁₋₂₀alkyl)₂, (CR₁₂R_{12'})_mNHC₁₋₂₀alkenyl, (CR₁₂R_{12'})_mN(C₁₋₂₀alkenyl)₂, (CR₁₂R_{12'})_mNHC(O)C₁₋₂₀alkyl, (CR₁₂R_{12'})_mNHC(O)C₁₋₂₀alkenyl, (CR₁₂R_{12'})_mNHC(O)aryl, (CR₁₂R_{12'})_mNH[C(O)CH(R₂₁)NH]_r-H, (CR₁₂R_{12'})_mNH-
 30 [sugar]_r, (CR₁₂R_{12'})_mSO₃H, (CR₁₂R_{12'})_mSO₃C₁₋₂₀alkyl, (CR₁₂R_{12'})_mSO₃C₁₋₂₀alkenyl,

- 11 -

- $(\text{CR}_{12}\text{R}_{12'})_m\text{C}(\text{O})\text{C}_{1-20}\text{alkyl}$, $(\text{CR}_{12}\text{R}_{12'})_m\text{C}(\text{O})\text{C}_{1-20}\text{alkenyl}$, $(\text{CR}_{12}\text{R}_{12'})_m\text{CO}_2\text{H}$,
 $(\text{CR}_{12}\text{R}_{12'})_m\text{CO}_2\text{C}_{1-20}\text{alkyl}$, $(\text{CR}_{12}\text{R}_{12'})_m\text{CO}_2\text{C}_{1-20}\text{alkenyl}$, $(\text{CR}_{12}\text{R}_{12'})_m\text{C}(\text{O})\text{NHC}_{1-20}\text{alkyl}$,
 $(\text{CR}_{12}\text{R}_{12'})_m\text{C}(\text{O})\text{N}(\text{C}_{1-20}\text{alkyl})_2$, $(\text{CR}_{12}\text{R}_{12'})_m\text{C}(\text{O})\text{NHC}_{1-20}\text{alkenyl}$, $(\text{CR}_{12}\text{R}_{12'})_m\text{C}(\text{O})\text{N}(\text{C}_{1-20}\text{alkenyl})_2$,
 $(\text{CR}_{12}\text{R}_{12'})_m\text{C}(\text{O})[\text{NHCH}(\text{R}_{21})\text{C}(\text{O})]_r\text{OH}$, $(\text{CR}_{12}\text{R}_{12'})_m\text{C}(\text{O})[\text{sugar}]_r$; wherein
 5 each R_{12} and $\text{R}_{12'}$ is independently selected from hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, halogen, OH, $\text{OC}_{1-6}\text{alkyl}$, CO_2H , $\text{CO}_2\text{C}_{1-3}\text{alkyl}$, NH_2 , $\text{NHC}_{1-3}\text{alkyl}$, $-\text{N}(\text{C}_{1-3}\text{alkyl})_2$,
 CN, NO_2 , aryl or heterocyclyl; R_{21} is the characterising group of an amino acid, m is 0 or
 an integer from 1 to 20 and r is an integer from 1 to 5;
- 10 R_3 is hydrogen, $\text{C}_{1-6}\text{alkyl}$, $-(\text{CH}_2)_n\text{NH}_2$, $-(\text{CH}_2)_n\text{OH}$, $-(\text{CH}_2)_n\text{CF}_3$ or $-(\text{CH}_2)_n\text{SH}$ wherein
 n is 0 or an integer from 1 to 3;

R_4 is hydrogen, methyl, fluoro or halo;

- 15 At least one of R_5 and $\text{R}_{5'}$ is hydrogen;


At least one of R_{12} and $\text{R}_{12'}$ is hydrogen;

At least one of R_{16} and $\text{R}_{16'}$ is hydrogen;

20

At least one of R_{26} and $\text{R}_{26'}$ is hydrogen;

In certain preferred forms of the invention, the compounds of Formula (I) include:



25

BEST AVAILABLE COPY

- 12 -

wherein

X is -O-, -S-, -C(R₅)₂- or -N(R₆)-;

5 Y is -N(R₇)- or -C(R₇)₂-;

Z is -C(O)-, -C(S)- or -C(=NR₆)

R₁ is hydrogen, OH, SH, NH₂, F or Cl;

10

R₂ is C₁-C₂₀alkyl, C₂-C₂₀alkenyl, C₂-C₂₀alkynyl, (CR₁₂R_{12'})_mC(O)R₈, -(CR₁₂R_{12'})_mC(S)R₈, -(CR₁₂R_{12'})_mS(O)R₈, -(CR₁₂R_{12'})_mS(O)₂R₈, -(CR₁₂R_{12'})_mOR₉, -(CR₁₂R_{12'})_mSR₉, -(CR₁₂R_{12'})_mNR₁₀R₁₁, (CR₁₂R_{12'})_mC(=NR₂₄)R₂₂ or (CR₁₂R_{12'})_mR₁₃ where m, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, R_{12'}, R₂₂ and R₂₄ are defined above;


15

R₃ is hydrogen, C₁₋₆alkyl, -(CH₂)_nNH₂, -(CH₂)_n-OH, -(CH₂)_nCF₃ or -(CH₂)_nSH where n is defined above;

R₄ is hydrogen.

20

More preferably the compounds of formula (I) comprise



wherein

25 X is -N(R₆)-;

- 13 -

Y is -N(R₇)- or -C(R₇)₂-;

Z is -C(O)-, -C(S)- or -C(=NH);

5

R₁ is hydrogen, F or Cl;


R₂ is as defined for R₂ above;

10 R₃ is hydrogen, C₁₋₃alkyl, (CH₂)_nNH₂, (CH₂)_nOH or (CH₂)_nCF₃ where n is defined above;

R₄ is hydrogen.

Most preferably, the compounds of Formula (I) are benzimidazole compounds having the

15 formula (II)





wherein

20 R₁ is hydrogen, F or Cl;





R₂ is as defined for R₂ above;

R₃ is hydrogen, C₁₋₃alkyl, (CH₂)_nNH₂, (CH₂)_nOH, (CH₂)_nCF₃ where n is defined above.





Examples of suitable compounds may include



5




10



Compounds of Formula (I) may be prepared using the methods depicted or described herein or known in the art. It will be understood that minor modifications to methods described herein or known in the art may be required to synthesize particular compounds of Formula (I). General synthetic procedures applicable to the synthesis of compounds
 5 may be found in standard references such as *Comprehensive Organic Transformations*, R. C. Larock, 1989, VCH Publishers and *Advanced Organic Chemistry*, J. March, 4th Edition (1992), Wiley InterScience, and references therein. It will also be recognised that certain reactive groups may require protection and deprotection during the synthetic process. Suitable protecting and deprotecting methods for reactive functional groups are known in
 10 the art for example in *Protective Groups in Organic Synthesis*, T. W. Green & P. Wutz, John Wiley & Son, 3rd Edition, 1999.

Thus, for certain embodiments of the invention, compounds of Formula (I), where X and Y are N and Z is -C(O)-, -S(O)- or -(C=NR₆)- may be prepared in accordance with the
 15 exemplified general methods depicted in scheme 1 (3). Suitable starting materials can be obtained commercially or prepared using methods known in the art.



Scheme 1


20

When R is -CO₂H or -C(S)OH, the compounds may be further derivatised to provide ketones, thioketones, esters, thioesters, amides and thioamides by standard alkylating, esterifying or amide forming methodology. When R is hydroxy, thiol or amino, these groups may be further derivatised to provide esters, thioesters, amides, ethers, thioethers
 25 and N-alkyl groups using standard acylating or alkylating methodology. Conversion of an amide to C=NH(NH₂) can be achieved by aminolysis eg NH₃/dry methanol.

When R is CO₂H, a methylene group can be inserted between the benzene nucleus and the carboxylic acid group by Arndt-Eistert synthesis, eg by conversion of the carboxylic acid to an acyl halide and conversion to the diazoketone. Rearrangement of the diazoketone (eg with silver oxide and water) affords access to the CH₂-CO₂H group. Repeating these steps
 5 allows for further incorporation of methylene groups. The CO₂H group can be converted as above.


In other embodiments, compounds of Formula (I), where R₂ is a substituted methyl group, can be prepared by conversion of the methyl substituent (R₂) into a halomethyl substituent
 10 (eg by treatment with a N-halosuccinimide such as NBS) followed by nucleophilic substitution by an appropriate nucleophile and/or insertion of additional methylene groups by, for example, Wittig reaction (see Scheme 2 where R* can be, for example, (CH₂)_mOH, (CH₂)_mSH, (CH₂)_mNH₂, (CH₂)_mC(O)C₁₋₂₀alkyl, (CH₂)_mOC(O)C₁₋₁₀alkyl, (CH₂)_mOC₁₋₂₀alkyl, (CH₂)_mOphenyl, (CH₂)_mObenzyl, (CH₂)_mNHC₁₋₂₀alkyl, (CH₂)_mN(C₁₋₂₀alkyl)₂,
 15 (CH₂)_mNHphenyl, (CH₂)_mNHbenzyl, (CH₂)_mSC₁₋₂₀alkyl, (CH₂)_mSC(O)C₁₋₁₀alkyl, (CH₂)_mSphenyl, (CH₂)_mSbenzyl, (CH₂)_mNHsugar, (CH₂)_mSsugar, (CH₂)_mOsugar, (CH₂)_mNHC(O)C₁₋₁₀alkyl, (CH₂)_mNHC(O)phenyl, (CH₂)_mNHC(O)benzyl, (CH₂)_mNHCO₂C₁₋₆alkyl, (CH₂)_mNHCO₂phenyl, or (CH₂)_mNHCO₂benzyl, where m is 0 or 1 to 20).

- 17 -

**Scheme 2**

In other embodiments, compounds where R₂ is CH₂halo can be prepared by reaction of a
5 suitable carboxylic acid derivative with a reducing agent such as LiAlH₄, followed by
halogenation, eg treatment with thionyl chloride (Scheme 3).

- 18 -




Scheme 3

Coupling of compounds wherein R_2 is CH_2halo with a C_{1-6} alkylhalide, halo $(\text{CH}_2)_n$ heterocyclyl in the presence of CuLi affords the corresponding compounds where the R_2 substituent is C_{1-6} alkyl, $(\text{CH}_2)_n$ heterocyclyl.

Reaction of CH_2halo with $\text{NH}_2\text{-NH-C(=NH)-NH}_2$ in the presence of base affords access to compounds wherein R_2 is $\text{CH}_2\text{-NH-NH-C(=NH)-NH}_2$. Alternatively, reaction of the CH_2halo group with halo $(\text{CH}_2)_p\text{NH-NH-C(=NH)-NH}_2$ (where p is 1 or 2), affords the group $(\text{CH}_2)_p\text{NH-NH-C(=NH)-NH}_2$ where p is 2 or 3.

Other embodiments of formula I may be prepared by known methods. For example, furan, thiophene and indole derivatives may be prepared by cyclisation of hydroxy acids, thiol acids or amino acids respectively. For example,

- 19 -



Scheme 4

The term "salt, or prodrug" includes any pharmaceutically acceptable salt, ester, solvate, hydrate or any other compound which, upon administration to the recipient is capable of providing (directly or indirectly) a compound of Formula (I) as described herein. The term "pro-drug" is used in its broadest sense and encompasses those derivatives that are converted *in vivo* to the compounds of the invention. Such derivatives would readily occur to those skilled in the art, and include, for example, compounds where a free hydroxy group is converted into an ester, such as an acetate, or where a free amino group is converted into an amide. Procedures for acylating hydroxy or amino groups of the compounds of the invention are well known in the art and may include treatment of the compound with an appropriate carboxylic acid, anhydride or acylchloride in the presence of a suitable catalyst or base.

15

Suitable pharmaceutically acceptable salts include, but are not limited to, salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, maleic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benzenesulphonic, salicylic, salicylic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, -ascorbic and valeric acids.

25 Base salts include, but are not limited to, those formed with pharmaceutically acceptable cations, such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium.

BEST AVAILABLE COPY

Basic nitrogen-containing groups may be quarternised with such agents as lower alkyl halide, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others.

- 5 It will also be recognised that some compounds of formula (I) may possess asymmetric centres and are therefore capable of existing in more than one stereoisomeric form. The invention thus also relates to compounds in substantially pure isomeric form at one or more asymmetric centres eg., greater than about 90% ee, such as about 95% or 97% ee or greater than 99% ee, as well as mixtures, including racemic mixtures, thereof. Such
10 isomers may be prepared by asymmetric synthesis, for example using chiral intermediates, or by chiral resolution.

- As used herein, MIF includes human or other animal MIF and derivatives and naturally occurring variants thereof which at least partially retain MIF cytokine or biological
15 activity. Thus, the subject to be treated may be human or other animal such as a mammal. Non-human subjects include, but are not limited to primates, livestock animals (eg sheep, cows, horses, pigs, goats), domestic animals (eg dogs, cats), birds and laboratory test animals (eg mice rats, guinea pigs, rabbits). MIF is also expressed in plants (thus "MIF" may also refer to plant MIF) and where appropriate, compounds of Formula (I) may be
20 used in botanical/agricultural applications such as crop control.

- Reference herein to "cytokine or biological activity" of MIF includes the cytokine or biological effect on cellular function via autocrine, endocrine, paracrine, cytokine, hormone or growth factor activity or via intracellular effects.

25

- As used herein, the term "effective amount" relates to an amount of compound which, when administered according to a desired dosing regimen, provides the desired MIF cytokine inhibiting or treatment or therapeutic activity, or disease/condition prevention. Dosing may occur at intervals of minutes, hours, days, weeks, months or years or
30 continuously over any one of these periods. A cytokine or biological activity inhibiting amount is an amount which will at least partially inhibit the cytokine or biological activity

- 21 -

of MIF. A therapeutic, or treatment, effective amount is an amount of the compound which, when administered according to a desired dosing regimen, is sufficient to at least partially attain the desired therapeutic effect, or delay the onset of, or inhibit the progression of or halt or partially or fully reverse the onset or progression of a particular disease condition being treated. A prevention effective amount is an amount of compound which when administered according to the desired dosing regimen is sufficient to at least partially prevent or delay the onset of a particular disease or condition. A diagnostic effective amount of compound is an amount sufficient to bind to MIF to enable detection of the MIF-compound complex such that diagnosis of a disease or condition is possible.

10

Suitable dosages may lie within the range of about 0.1 ng per kg of body weight to 1 g per kg of body weight per dosage. The dosage is preferably in the range of 1 μ g to 1 g per kg of body weight per dosage, such as is in the range of 1 mg to 1 g per kg of body weight per dosage. In one embodiment, the dosage is in the range of 1 mg to 500 mg per kg of body weight per dosage. In another embodiment, the dosage is in the range of 1 mg to 250 mg per kg of body weight per dosage. In yet another preferred embodiment, the dosage is in the range of 1 mg to 100 mg per kg of body weight per dosage, such as up to 50 mg per kg of body weight per dosage. In yet another embodiment, the dosage is in the range of 1 μ g to 1 mg per kg of body weight per dosage.

20

Suitable dosage amounts and dosing regimens can be determined by the attending physician or veterinarian and may depend on the desired level of inhibiting activity, the particular condition being treated, the severity of the condition as well as the general age, health and weight of the subject.

25

The active ingredient may be administered in a single dose or a series of doses. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a composition, preferably as a pharmaceutical composition.

~~30 The formulation of such compositions is well known to those skilled in the art. The composition may contain pharmaceutically acceptable additives such as carriers, diluents~~

BEST AVAILABLE COPY

or excipients. These include, where appropriate, all conventional solvents, dispersion agents, fillers, solid carriers, coating agents, antifungal and antibacterial agents, dermal penetration agents, surfactants, isotonic and absorption agents and the like. It will be understood that the compositions of the invention may also include other supplementary
5 physiologically active agents.

The carrier must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the composition and not injurious to the subject. Compositions include those suitable for oral, rectal, inhalational, nasal, transdermal, topical (including
10 buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intraspinal, intravenous and intradermal) administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
15 In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

Depending on the disease or condition to be treated, it may or may not be desirable for a
20 compound of Formula (I) to cross the blood/brain barrier. Thus the compositions for use in the present invention may be formulated to be water or lipid soluble.

Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets or tablets each containing a predetermined amount
25 of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

30 A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine

the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (eg inert diluent, preservative, disintegrant (eg. sodium starch glycolate, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose)) surface-active or dispersing agent. Moulded tablets may be made by moulding in a
5 suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in
10 parts of the gut other than the stomach.

Compositions suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured base, usually sucrose and acacia or tragacanth gum; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or
15 sucrose and acacia gum; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

The compounds of Formula (I) may also be administered intranasally or via inhalation, for example by atomiser, aerosol or nebulizer means.
20

Compositions suitable for topical administration to the skin may comprise the compounds dissolved or suspended in any suitable carrier or base and may be in the form of lotions, gel, creams, pastes, ointments and the like. Suitable carriers include mineral oil, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax, sorbitan monostearate,
25 polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. Transdermal devices, such as patches, may also be used to administer the compounds of the invention.

Compositions for rectal administration may be presented as a suppository with a suitable
30 carrier base comprising, for example, cocoa butter, gelatin, glycerin or polyethylene glycol.

Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

5

Compositions suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bactericides and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind
15 previously described.

Preferred unit dosage compositions are those containing a daily dose or unit, daily sub-dose, as herein above described, or an appropriate fraction thereof, of the active ingredient.

20 It should be understood that in addition to the active ingredients particularly mentioned above, the compositions of this invention may include other agents conventional in the art having regard to the type of composition in question, for example, those suitable for oral administration may include such further agents as binders, sweeteners, thickeners, flavouring agents, disintegrating agents, coating agents, preservatives, lubricants and/or
25 time delay agents. Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine. Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar. Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring. Suitable coating agents include polymers or copolymers of acrylic acid and/or methacrylic
30 acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl

paraben, propyl paraben or sodium bisulphite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate.

5 It will be recognised that other therapeutically active agents such as anti-inflammatory (eg steroids such as glucocorticoids) or anti-cancer agents may be used in conjunction with a compound of Formula (I). Compounds of Formula (I) when administered in conjunction with other therapeutically active agents may exhibit an additive or synergistic effect. These may be administered simultaneously, either as a combined form (ie as a single
10 composition containing the active agents) or as discrete dosages. Alternatively, the other therapeutically active agents may be administered sequentially or separately with the compounds of the invention. Thus, the invention also relates to kits and combinations, comprising a compound of Formula (I) and one or more other therapeutically active ingredients for use in the treatment of diseases or conditions described herein.

15

Examples of suitable glucocorticoids' include but are not limited to prednisolone, prednisone, cortisone acetate, beclamethasone, fluticasone, hydrocortisone and dexamethasone. A person skilled in the art would be able to identify other suitable glucocorticoids that may benefit from being used in a combination treatment with a MIF
20 antagonist.

Glucocorticoids may be administered in single, daily or divided doses or as a continuous infusion. When administered orally, intravenously, intramuscularly, intralesionally or intra-cavity (e.g. intra-articular, intrathecal, intra-thoracic), dosages are typically between 1
25 mg to 1000 mg, preferably 1 mg to 100 mg, more preferably 1 mg to 50 mg or 1 mg to 10 mg per dose. When administered topically or by inhalation as a single, daily or divided dose, dosages are typically 1 ng to 1 µg, 1 ng to 1 mg, or 1 pg to 1 µg.

In one preferred aspect of the invention, the compounds of formula (I) may be
30 administered together with, simultaneously or sequentially, glucocorticoids. In such a therapy, the amount of glucocorticoid required may be significantly reduced.

The compounds of the invention may also be presented for use in veterinary compositions. These may be prepared by any suitable means known in the art. Examples of such compositions include those adapted for:

5

- (a) oral administration, external application (eg drenches including aqueous and non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pellets for admixture with feedstuffs, pastes for application to the tongue;
- (b) parenteral administration, eg subcutaneous, intramuscular or intravenous injection
10 as a sterile solution or suspension; and
- (c) topical application eg creams, ointments, gels, lotions, etc.

By virtue of their ability to bind to or antagonize MIF, compounds of Formula (I) or salts or derivatives thereof may be used as laboratory or diagnostic or *in vivo* imaging reagents.

- 15 Typically, for such use the compounds would be labelled in some way, for example, radio isotope, fluorescence or colorimetric labelling, or be chelator conjugated. In particular, compounds of Formula (I) could be used as part of an assay system for MIF or as controls in screens for identifying other inhibitors. Those skilled in the art are familiar with such screens and could readily establish such screens using compounds of Formula (I). Those
20 skilled in the art will also be familiar with the use of chelate conjugated molecules for *in vivo* diagnostic imaging.

- Unless the context indicates otherwise, reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior
25 art forms part of the common general knowledge in Australia.

- Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications which fall within the spirit
30 and scope. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and

any and all combinations of any two or more of said steps or features.


The invention will now be described with reference to the following examples which are included for the purpose of illustration only and are not intended to limit the generality of the invention hereinbefore described.

EXAMPLES

Synthesis of compounds of Formula (I).

10 Example 1:

5-Methylbenzimidazol-2-one (2)



15 This was prepared as described by *Harvey et al* (3).


A solution of urea (6.00 g, 0.1000 mol) and 3,4-diaminotoluene (1) (12.20 g, 0.0999 mol) in pentan-1-ol (40 mL) was vigorously stirred and heated to reflux under a nitrogen atmosphere. After 2 hours the heating was discontinued and on cooling to room temperature a pink solid settled out. This was filtered off and recrystallised from boiling ethanol (17.98 g. in 400 mL) to give 2 crops of 5-methylbenzimidazol-2-one (2) as a pink powder. The total mass was recovered was 8.21 g (56 % yield);

R_f: 0.40 (9:1 CHCl₃:MeOH),

mp: 300-302 °C, lit.³ mp: 297-300 °C;

25 ¹H NMR (CDCl₃/CD₃OD): δ 2.12 (s, 3 H, CH₃), 6.63-6.70 (m, 3H, ArH);

LRESI mass spectrum: *m/z* 149 (100%, MH⁺).

Example 2:Benzimidazol-2-one-5-carboxylic acid (4)

5

The method described by *Harvey et al*³ and used in Example 1 for the preparation of 5-methylbenzimidazol-2-one (2) was used except this preparation started with 3,4-diaminobenzoic acid (3).

- 10 Urea (1.20 g, 0.0200 mol) and 3,4-diaminobenzoic acid (3) (3.04 g, 0.0200 mol) in pentan-1-ol (10 mL) was vigorously stirred and heated to reflux under a nitrogen atmosphere. The heating was discontinued after 4 hours and on cooling to room temperature, water (30 mL) was added. The pH was adjusted to 1 with conc. HCl. The resultant dark solid was filtered off, washed with further water (2 x 20 mL) and dried to give 3.00 g (84% yield) of
- 15 benzimidazol-2-one-5-carboxylic acid (4) as a black powder;


R_f : 0.09 (9:1 CHCl_3 :MeOH), 0.20 (4:1 CHCl_3 :MeOH),

^1H NMR (d_6 -DMSO): δ 6.98 (d, 1 H, $J_{7,6}$ 8.1 Hz, H-7), 7.45(d, 1 H, $J_{4,6}$ 1.2 Hz, H-4), 7.60 (dd, 1 H, H-6), 10.78 (bs, 1 H, NH), 10.94 (bs, 1 H, NH);

- 20 LRESI negative ion mass spectrum: m/z 177 (100%, M-H⁻).

Example 3:Benzimidazol-2-one-5-n-pentanoate (5)

- 29 -



5 Benzimidazol-2-one-5-carboxylic acid (4) (250 mg, 0.9070 mmol) and Dowex 50W-X8(H⁺) resin (250 mg) were suspended in pentan-1-ol (40 mL) and the mixture heated to reflux for 42 hours. The solid was filtered off and washed with methanol (3 x 20 mL) and the combined filtrates evaporated to dryness to give benzimidazol-2-one-5-*n*-pentanoate (5) (310 mg, 43% yield) as an off-white powder;

R_f: 0.63 (4:1 CHCl₃:MeOH),

10 mp: 227-228°C,

¹H NMR (CDCl₃/CD₃OD): δ 0.88-0.92 (pseudo t, 3 H, CH₃), 1.33-1.43 (m, 4 H, 2 x CH₂), 1.70-1.79 (m, 2 H, CH₂), 4.25-4.29 (pseudo t, 2 H, CH₂), 7.04 (d, 1 H, *J*_{7,6} 8.4 Hz, H-7), 7.44 (bs, 1 H, NH), 7.55 (bs, 1 H, NH), 7.66 (bs, 1 H, H-4), 7.75 (dd, 1 H, *J*_{6,5} 1.5 Hz, H-6);

15 LRESI negative ion mass spectrum: *m/z* 247 (100%, [M-H]⁻);


HRESI positive ion mass spectrum: C₁₃H₁₇N₂O₃ calculated 249.12391,

C₁₃H₁₆N₂O₃ calculated C, 62.97; H, 6.50; N, 11.29, found C, 63.1, H, 6.54, N, 11.05.

Example 4:

20 5 [2(1-oxy-2-hydroxyethyl)ethyl] benzimidazol-2-one-5-carboxylate (6)

- 30 -



Benzimidazol-2-one-5-carboxylic acid (**4**) (300 mg, 1.6853 mmol) and Dowex 50W-X8(H⁺) resin (300 mg) were suspended in diethylene glycol (50 mL) and the mixture heated to reflux for 44 hours. The solid was filtered off and washed with methanol (3 x 20 mL) and the combined filtrates reduced in volume (approx 2 mL) with vacuum distillation. This residue was column chromatographed (SiO₂, isocratically with 4:1 CHCl₃:MeOH) to give with evaporated to dryness to give 5 [2(1-oxy-2-hydroxyethyl)ethyl] benzimidazol-2-one-5-carboxylate (**6**) (310 mg, 43% yield) as an off-white powder;


R_f: 0.63 (4:1 CHCl₃:MeOH),

mp: 227-228°C,

¹H NMR (CDCl₃/CD₃OD): δ 0.88-0.92 (pseudo t, 3 H, CH₃), 1.33-1.43 (m, 4 H, 2 x CH₂), 1.70-1.79 (m, 2 H, CH₂), 4.25-4.29 (pseudo t, 2 H, CH₂), 7.04 (d, 1 H, J_{7,6} 8.4 Hz, H-7), 7.44 (bs, 1 H, NH), 7.55 (bs, 1 H, NH), 7.66 (bs, 1 H, H-4), 7.75 (dd, 1 H, J_{6,5} 1.5 Hz, H-6);

LRESI negative ion mass spectrum: m/z 247 (100%, [M-H]⁻);

Example 5:



Benzimidazol-2-one 5 carboxylic acid (**4**) (100 mg; 0.56 mmol) and DCC (100 mg) were suspended in methanol and the mixture heated to reflux for 42 hours. The solid was filtered off and washed with methanol (3 x 3 mL) and the combined filtrates evaporated to dryness to give benzimidazol-2-one-5-methanoate (**7**) in 61% yield.


5

$^1\text{HMR}(\text{d}_6\text{-DMSO})$: δ 3.80 (s, 3H, CO_2CH_3), 6.70 (d, 1H, J_{ortho} 8.1 Hz, aromatic), 7.46 (bs, 1H, 4-H aromatic), 7.61 (d, 1H, J_{ortho} 8.1 Hz, aromatic), 10.82 (bs, 1H, NH) and 10.99 (bs, 1H, NH).

Negative ion mass spectrum: m/z 191 (40%, $\text{M}-1^+$).

10

Example 6:



15 Benzimidazol-2-one 5 carboxylic acid (**4**) (100 mg) and conc. H_2SO_4 (0.25 mL) were suspended in ethanol and the mixture heated to reflux for 20 hours. The solid was filtered off and washed with ethanol (50 mL) and the combined filtrates evaporated to dryness to give benzimidazol-2-one-5-ethanoate (**8**) in 69% yield.


20 $^1\text{HMR}(\text{d}_6\text{-DMSO})$: δ 1.20 (t, 3H, $J=6.9$ Hz, CH_3 -), 4.26 (q, 2H, $J=6.9$ Hz, OCH_2 -), 7.00 (d, 1H, J_{ortho} 8.1 Hz, H-7 aromatic), 7.46 (d, 1H, J_{meta} 1.5 Hz, 4-H aromatic), 7.62 (dd, 1H, J_{ortho} 8.2 Hz and J_{meta} 1.5 Hz, 6-H aromatic) and 10.88 (bs, 2H, NH).

Negative ion mass spectrum: M/Z 205 (100%, $\text{M}-1^+$).

25 Example 7:

Benzimidazol-2-one-5- Serine-amido- coupled adduct (9)

- 32 -



A suspension of benzimidazol-2-one-5-carboxylic acid (4) (356 mg, 2.00 mmol) and L-serine-methylester hydrochloride (311 mg, 2.00 mmol) in sieve dried DMF (6 mL) was cooled in an ice-bath. Then added, in the following sequence, were 1-hydroxybenzotriazole monohydrate (612 mg, 4.00 mmol), diisopropylethylamine (0.696 mL, 517 mg, 4.00 mmol, Hunnig's Base) and 1,3-dicyclohexylcarbodiimide (412 mg, 2.00 mmol). The reaction was allowed to equilibrate to room temperature and left to stir for 41 hours.


The white solid dicyclohexylurea was then filtered off and washed with further DMF (5 mL). The combined filtrates were then vacuum distilled to give a black oil (2.09 g). This was triturated with chloroform (20 mL) over ice to give a dark solid that was filtered off. A sample (250 mg) was made up as a DMF bolus and this column chromatographed (SiO₂, isocratically eluted with 4:1 CHCl₃:MeOH) to give 208 mg of the benzimidazol-2-one-5-Serine-amido- coupled adduct (9) as a pale brown powder;

R_f: 0.41 (4:1 CHCl₃:MeOH),

¹H NMR (d₆-DMSO): δ 3.63 (s, 3 H, CO₂CH₃), 3.75-3.79(pseudo t, 2 H, CH₂), 4.48-4.54(m, 1 H, CH), 5.00(t, 1 H, OH), 6.97(d, 1 H, J_{7,6} 8.1 Hz, H-7), 7.47(bs, 1 H, H-4), 7.54 (dd, 1 H, J_{6,5} 1.5 Hz, H-6), 8.35 (d, 1 H, J_{NH} 7.5 Hz, NH), 10.83 (bs, 2 H, 2 x NH);

LRESI mass spectrum: *m/z* 280 (100%, MH⁺).


Example 8:

Deprotected benzimidazol-2-one-5-carbox-(L-serine)-amide adduct (10)

- 5 The methyl ester adduct benzimidazol-2-one-5-carboxy-(L-serine)-amide (**9**) (100 mg, 0.3584 mmol) was suspended in methanol (10 mL) and on addition of 1M aq NaOH (0.68 mL, 0.680 mmol) readily dissolved. The disappearance of starting material was monitored with TLC and complete after stirring overnight at room temperature. The volume was increased by addition of further methanol (30 mL) and the pH carefully adjusted from 10
- 10 to 5 by the addition of Dowex 50W-X8(H⁺) resin. The resin was rapidly filtered off and washed with further methanol (4 x 20 mL) and the combined filtrates rotary evaporated to dryness to give benzimidazol-2-one-5-carboxy-(L-serine)-amide (**10**) (91 mg, 96% yield) as a white powder;
- 15 $R_f \leq 0.04$ (4:1 CHCl₃:MeOH),
¹H NMR (d₆-DMSO): δ 3.74-3.80(m, 2 H, CH₂), 4.38-4.45(m, 1 H, CH), 6.97(d, 1 H, $J_{7,6}$ 8.1 Hz, H-7), 7.46 (bs, 1 H, H-4), 7.53 (dd, 1 H, $J_{6,5}$ 1.5 Hz, H-6), 8.16 (d, 1 H, J_{NH} 7.5 Hz, NH);
 LRESI mass spectrum: positive ion m/z 266 (100%, MH⁺), negative ion m/z 264 (100%, [M-H]⁻).
- 20

Example 9:Benzimidazol-2-one-5-Phenylalanine-amido-coupled adduct (11)

- 34 -



A suspension of benzimidazol-2-one-5-carboxylic acid (**4**) (356 mg, 2.00 mmol) and L-phenylalanine-methylester hydrochloride (431 mg, 2.00 mmol) in sieve dried DMF (6 mL) was cooled in an ice-bath. Then added, in the following sequence, were 1-hydroxybenzotriazole monohydrate (612 mg, 4.00 mmol), diisopropylethylamine (0.696 mL, 517 mg, 4.00 mmol, Hunnig's Base) and 1,3-dicyclohexylcarbodiimide (412 mg, 2.00 mmol). The reaction was allowed to equilibrate to room temperature and left to stir for 44 hours.

The white solid dicyclohexylurea was then filtered off and washed with further DMF (5 mL). The combined filtrates were then vacuum distilled to give a black oil (2.00 g). This was column chromatographed (SiO₂, isocratically eluted with 6:1 CHCl₃:MeOH) to give as main product 1.15 g of a brown solid. 150 mg was taken and this then rechromatographed (SiO₂, isocratically eluted with 9:1 CHCl₃:MeOH) to give 81 mg (equivalent to 90% overall yield) of the benzimidazol-2-one-5-phenylalanine-amido-coupled adduct (**11**) as an off white powder;

R_f: 0.38 (9:1 CHCl₃:MeOH),

mp: 220-221°C;

¹H NMR (CDCl₃/CD₃OD): δ 3.06-3.13 (m, 2 H, CH₂), 3.63 (s, 3 H, CO₂CH₃), 4.86 (pseudo t, 1 H, CH), 6.90 (bd, 1 H, *J* 8.1 Hz), 7.03-7.05 (m, 2 H),


7.10-7.18 (m, 3 H), 7.28-7.31 (m, 2 H, *J* 8.1 Hz, *J* 1.5 Hz);

LRESI mass spectrum: *m/z* 340 (41%, MH⁺), 225 (100%).

Example 10:

Deprotected benzimidazol-2-one-5-phenylalanine-amido-coupled adduct (**12**)

- 35 -



1M aq NaOH (0.75 mL, 0.75 mmol) was added to the methyl ester adduct of
 5 benzimidazol-2-one-5-carbox-(L-phenylalanine)-amide (11) (65 mg, 0.1917 mmol)
 dissolved in methanol (7.5 mL) and this stirred overnight at room temperature. The
 volume was increased then increased to 50 mL by the addition of further methanol and the
 pH then carefully adjusted from 10 to 5 by the addition of Dowex 50W-X8(H⁺) resin. The
 resin was rapidly filtered off, washed with further methanol (4 x 20 mL) and the combined
 10 filtrates rotary evaporated to dryness to give an oil. This was taken up in hot ethanol and
 on cooling a white solid settled out from solution. This was filtered off and dried to give
 benzimidazol-2-one-5-carbox-(L-phenylalanine)-amide (12) (60 mg, 97% yield) as a white
 powder;

15 $R_f \leq 0.03$ (9:1 CHCl₃:MeOH),

mp: 222-223 °C,


¹H NMR (CD₃OD): δ 3.13 (dd, 1 H, J_{geminal} 13.5 Hz, J 7.8 Hz, benzyl-CH₂), 3.34 (dd, 1 H,
 benzyl-CH₂), 4.76 (pseudo t, 1 H, J 7.5 Hz, CH), 7.03 (bd, 1 H, J 8.1 Hz), 7.12-7.27 (m, 5
 H), 7.43-7.47 (m, 2 H, J 8.4 Hz, J 1.5 Hz);

20 LRESI mass spectrum: m/z 326 (100%, MH⁺).

Example 11:

Benzimidazol-2-one-5-dopamine-amido-coupled adduct (13)

- 36 -



A suspension of benzimidazol-2-one-5-carboxylic acid (4) (356 mg, 2.00 mmol) and 3,4-dihydroxyphenylethylamine hydrochloride (379 mg, 2.00 mmol) in sieve dried DMF (6 mL) was cooled in an ice-bath. Then added, in the following sequence, were 1-hydroxybenzotriazole monohydrate (612 mg, 4.00 mmol), diisopropylethylamine (0.696 mL, 517 mg, 4.00 mmol, Hunnig's Base) and 1,3-dicyclohexylcarbodiimide (412 mg, 2.00 mmol). The reaction was allowed to equilibrate to room temperature and left to stir for 44 hours.


The white solid dicyclohexylurea was then filtered off and washed with further DMF (2 x 5 mL). The combined filtrates were then vacuum distilled to give a dark brown oil (2.39 g). This was taken up in methanol (5 mL) and on addition of chloroform (10 mL) a dark solid settled out of solution. This was filtered off, dissolved in a minimum amount of DMF and then subject to column chromatography (SiO₂, isocratically eluted with 4:1 CHCl₃:MeOH) to give 604 mg (96 % yield) of benzimidazol-2-one-5-dopamine-amido-coupled adduct (13) as a pale brown powder. A sample was triturated with cold 4:1 CHCl₃:MeOH, filtered and dried to give material for spectroscopic and bioassay analysis.

R_f: 0.38 (9:1 CHCl₃:MeOH),

mp: >250 °C, darkens without melting;

¹H NMR (d₆ DMSO): δ 2.49 (t, 2 H, *J* 1.8 Hz, CH₂), 2.62 (t, 2 H, *J* 7.8 Hz, CH₂), 6.45 (dd, 1 H, *J*_{6,5'} 8.1, *J*_{6,2'} 1.8 Hz, H-6') 6.60-6.64 (m, 2 H, H-2', H-5'), 6.94 (d, 1 H, *J*_{7,6} 8.4 Hz, H-7), 7.42 (bs, 1 H, H-4), 7.47 (dd, 1 H, *J*_{6,4} 1.5 Hz, H-4), 8.33 (bt, 1 H, *J* 5.4 Hz, amide NH), 8.63 (bs, 1 H, hetero NH), 8.73 (bs, 1 H, hetero NH);

LRESI mass spectrum: *m/z*, negative ion 312 (63%, [M-H]⁻), (249, 39%), (134, 100%); positive ion 314 (37%, MH⁺), (211, 69%), (130, 100%).

Example 12:benzimidazol-2-thio-5-carboxylic acid (14)

5

3

The method described by Harvey *et al.*³ and used in Example 2 for the preparation of benzimidazol-2-one-5-carboxylic acid (4) was used except this preparation used thiourea instead of urea.

10

Thiourea (1.52 g, 2 mmol) and 3,4-diaminobenzoic acid (3) (3.04 g, 2 mmol) in pentan-1-ol (14 ml) was stirred vigorously and heated to reflux under nitrogen atmosphere. Heating was discontinued after 5 hours, and stirring continued for 12 hours. Water was added and the pH adjusted to 1. The solvents were removed and the black solid was triturated with cold water (10 ml) and filtered to give 1.94 g of a black powder.

15

LRESI negative ion in mass spectrum: m/z 193 ($M-H$).

Biological testing20 *In vitro* assay of MIF antagonism

The activity of each compound was studied in a bioassay utilising MIF-dependent activation of human dermal fibroblasts. Sampey *et al* (4) have shown that induction of the expression of cyclooxygenase-2 (COX-2) by the cytokine interleukin 1 (IL-1) is dependent upon the presence of MIF, i.e. can be prevented using specific anti-MIF monoclonal

25 antibody. IL-1-induced COX-2 expression is therefore a MIF-dependent event.

S112 human dermal fibroblasts were propagated in RPMI/10% foetal calf serum (FCS). Prior to experimentation, cells were seeded at 10^5 cells/ml in RPMI/0.1% BSA for 18 hours. Cells were treated with recombinant human IL-1 (0.1 ng/ml) and with each compound at 1-100 μ M. A control was treated only with recombinant human IL-1 (0.1 ng/ml). After 6 hours, cells were collected and intracellular COX-2 protein determined by permeabilisation flow cytometry. Cells permeabilised with 0.1% saponin were sequentially labelled with a mouse anti-human COX-2 monoclonal antibody and with sheep-anti-mouse F(ab)2 fragment labelled with fluorescein isothiocyanate. Cellular fluorescence was determined using a flow cytometer. At least 5000 events were counted for each reading, each of which was performed in duplicate, and the results expressed in mean fluorescence intensity (MFI) after subtraction of negative control-labelled cell fluorescence.

The effect of each compound was determined by subtracting the IL-1+compound-treated cell MFI from the IL-1-treated cell (control) MFI and expressed as % inhibition.

Results are shown in Table 1 below where average % inhibition is shown. All samples contained 50 μ M of test compound.

Table 1

Compound	% inhibition	Number of experiments
5	-43.4	9
13	-13.4	4
6	-6.8	5
8	-13.2	5
12	-0.3	5

Figure 1 shows dose response curves for compound 5 observed in 3 experiments where compound 5 was added in 1 μ M, 10 μ M, 50 μ M and 100 μ M quantities and the samples analysed for IL-1 induced COX-2 expression as above.

Effect of glucocorticoids on MIF antagonism

In vitro assay of MIF antagonism in presence of glucocorticoid.

The above *in vitro* assay for analysing IL-1 induced COX-2 expression was repeated using Compound 5 (50 μ M), dexamethasone (10^{-9} M) or a combination of dexamethasone (10^{-9} M) and Compound 5 (50 μ M). The results are shown in Table 2 and Figure 2.

Table 2

Experiment	Compound	% Inhibition
1	Compound 5	-45.1
2	Dexamethasone	-46.8
3	Compound 5 + dexamethasone	-73.6

In vivo assay of MIF antagonism

The activity of compound 5 was studied in the murine endotoxic shock model. This model has been previously shown to be dependent on MIF (5). Endotoxaemia was induced by intra-peritoneal injection of lipopolysaccharide (LPS) (15mg/kg) in 400 μ l saline. Mice were treated with a saline solution (control) only, a saline solution and LPS or compound 5 at a dose of 15 mg/kg body weight by intra-peritoneal injection at 24 hours, 12 hours and 1 hour before intra-peritoneal LPS injection. After 24 hours mice were humanely killed by CO₂ inhalation then neck dislocation. Serum was obtained from blood obtained by cardiac puncture prior to death and measured for cytokines including interleukin 1 (IL-1) and interleukin 6 (IL-6) by ELISA. The production of IL-1 and IL-6 has been previously shown to be dependent on MIF (6). Macrophages were obtained by lavage of the peritoneal cavity using normal saline and placed into 24 well tissue culture plates for 18 hours in RPMI/10%FCS. The cultured peritoneal macrophage supernatants were then analysed for cytokines including IL-6. The peritoneal lavage supernatants were also analysed for cytokines including IL-6. The results are provided in Table 3 and Figure 3.

Table 3

Experiment	Serum IL-6 (ng/ml)	Cultured peritoneal macrophage IL-6 (ng/ml)	Peritoneal lavage IL-6 (ng/ml)
control	8.81	3.39	0
LPS only	261.05	3.40	16.11
LPS + compound 5	99.78	1.33	7.07

Figure 4 shows analysis of IL-1 (ng/ml) when LPS is administered alone or in combination with compound 5.

5

In vitro toxicity assay

The compounds of formula (I) may have low toxicity towards cells. The toxicity of compounds of formula (I) were examined *in vitro* to assess cytotoxicity. Human dermal fibroblast cell line (S112) cells were exposed to vehicle (control), compounds of formula (I) (50 μ M) or sodium nitroprusside (SNP) (0.5 μ M). SNP is a positive control agent which induces dose-dependent apoptosis in S112 cells. Toxicity was assessed by analysis of apoptosis using flow cytometric detection of cell surface Annexin V binding and propidium iodide staining. At least 5000 events were analysed for each experiment. Cells positive for both Annexin V and propidium iodide were designated as apoptotic and cells negative for both Annexin V and propidium iodide were designated as viable. Results are expressed as the percentage (%) of cells with each of these labels. No compound of formula (I) induced apoptosis at levels above the control whereas SNP induced a high level of apoptosis. The results for compound 5 are shown in Figure 5. The results for a number of compounds of formula (I) are shown in Figure 6.

References

- (1) David, J. Proc. Natl. Acad. Sci., USA, (1966), 56, 72-77.
- (2) Weiser, W. Y., *et al.*, Proc. Natl. Acad. Sci., USA, (1989), 86, 7522-7526.
- 5 (3) Harvey, *et al.*, J. Chem. Soc. Perkin Trans., 1, (1988), 681-689.
- (4) Sampey, A. V., *et al.*, Arthritis Rheum., 44, (2001), 1273-1280.
- (5) Bernhagen, J. et al., Nature, 365, 1993, (1999), 756-759.
- (6) Bozza, *et al.*, J. Exp. Med., 189, (1999), 341-346.

Figure 1





Figure 2



BEST AVAILABLE COPY

Figure 3





Figure 4



BEST AVAILABLE COPY

Figure 5





Figure 6



BEST AVAILABLE COPY